CMS has expanded Medicare coverage for Personalis’ NeXT Personal MRD test, now allowing immunotherapy monitoring in late-stage solid tumor patients, supported by recent clinical evidence from Vall d’Hebron Institute of Oncology.
Laboratories are leveraging established diagnostic and surveillance tools to track the Andes hantavirus outbreak linked to a cruise ship, with experts noting no evidence of widespread community transmission or efficient airborne spread.
LiquidCell Dx has published research in Nature on LiquidTME, a blood-based assay that profiles the tumor microenvironment and predicts immunotherapy response, potentially offering a noninvasive alternative to tissue biopsy.
Avant Genomics has secured over $3 million in funding to develop its Avant Source platform, which aims to automate liquid biopsy sample preparation and improve cell-free DNA recovery.
New research indicates that standard and modified two-tiered testing algorithms fail to detect infection in up to 78% of patients during the early stages of the disease.
